Skip to content

Surgical and Endovascular Repair

TL;DR — Elective replacement of the root/ascending aorta is now a low-mortality operation (~2.2% nationally for elective root replacement; ~1–3% in high-volume series) — which is precisely why prophylactic thresholds exist, because the same anatomy repaired emergently after type A dissection kills ~18–25% in hospital. Volume matters at every level: root-replacement mortality rises below ~30–40 aortic cases/year per hospital, and dissection repair mortality nearly doubles from highest- to lowest-volume surgeons. The root menu spans supracoronary replacement, composite valve-graft (Bentall 1968), and valve-sparing reimplantation (David) — the last now with 20-year data showing ~6% cumulative valve reoperation. Arch disease is handled by hemiarch, total arch, and staged or frozen elephant trunk; descending/thoracoabdominal disease splits between TEVAR (first-line when anatomy suits, in non-syndromic patients) and open repair with CSF drainage for spinal protection (RCT-proven, 80% relative risk reduction in paraplegia). The ascending aorta is TEVAR's last frontier (ARISE early feasibility), and PEARS offers a personalized external support with striking observational results in Marfan. Everything here is observational surgery science — there is no RCT comparing repair strategies for aneurysm.

Indications (summary)

Size, growth, symptoms, genotype and index-based triggers are tabulated with COR/LOE in guidelines; the intellectual history is in risk stratification. Headline anchors: 5.5 cm sporadic root/ascending (Class 1), 5.0 cm at experienced Multidisciplinary Aortic Team centers (2a), 5.0 cm Marfan (Class 1), growth ≥0.3 cm/yr ×2 yr (Class 1), descending ≥5.5 cm (Class 1) (Isselbacher 2022, PMID 36322642).

Open root and ascending repair

The menu

Operation What is replaced Valve fate Typical candidate
Supracoronary ascending replacement (interposition graft) Tubular ascending aorta only Native valve untouched (± separate AVR) Aneurysm isolated to ascending aorta; Class 1 B-NR when criteria met (Isselbacher 2022, PMID 36322642)
Composite valve-graft ("Bentall") Root + ascending, coronaries reimplanted Mechanical or biological prosthesis integral to graft Root aneurysm with unsalvageable valve; Class 1 B-NR (Bentall & De Bono 1968, PMID 5664694; Isselbacher 2022, PMID 36322642)
Valve-sparing root replacement — reimplantation (David) Root + ascending; valve resuspended inside graft Native valve preserved, annulus stabilized Younger patients, suitable cusps; 2a B-NR at experienced centers (David 2014, PMID 25527017; Isselbacher 2022, PMID 36322642)
Valve-sparing — remodeling (Yacoub) Root replaced with scalloped graft; annulus not encircled Native valve preserved, annular motion preserved Older patients with normal annulus; higher failure with connective-tissue disease/dilated annulus (Yacoub 1998, PMID 9605078; David 2014, PMID 25527017)

The Bentall composite graft (1968) made root aneurysm survivable and remains the reference operation (Bentall & De Bono 1968, PMID 5664694). Yacoub's remodeling series (158 patients from 1979, 68 with Marfan habitus) reported early mortality of 4.6% in the chronic-aneurysm subgroup (5/109), 0.97% for elective cases, and 11% reoperation probability at 10 years (Yacoub 1998, PMID 9605078).

Long-term valve-sparing data (Toronto)

  • All-comers reimplantation series: 465 consecutive patients (1989–2018; Marfan 164, LDS 13, BAV 67), operative mortality 5/465 (1.1%); at 20 years 69.1% alive and free of valve reoperation, cumulative valve reoperation 6.0%, moderate-severe AI 10.2%; AI accrues slowly with time (HR 1.06/yr) (David 2021, PMID 33008570).
  • Marfan-specific: 146 patients, median 10-yr follow-up; mortality at 15 yr 6.8%, AI 7.9%, valve reoperation in 5; new distal dissections were the leading cause of late death (15-yr dissection rate 16.5%) — sparing the valve does not spare the rest of the aorta (David 2015, PMID 26403341).
  • Reimplantation vs remodeling: comparative series favor reimplantation for durability in young/syndromic/dilated-annulus patients; remodeling performs well in older patients with normal annuli — patient selection, not superiority, explains most differences (David 2014, PMID 25527017).

The 2022 guideline codifies: valved conduit (mechanical or biological) Class 1 when the valve cannot be spared; VSRR 2a when the valve is sparable and the team experienced; mechanical vs biological conduits have similar long-term outcomes even under age 70 (Isselbacher 2022, PMID 36322642).

Elective vs emergency outcomes, and the volume–outcome relationship

Setting Mortality Source
Elective aortic root replacement, US national (STS database) 2.2% operative mortality cited in 2022 guideline (Isselbacher 2022, PMID 36322642)
Elective root/valve-ascending surgery, 13,358 patients, 741 North American hospitals 4.5% unadjusted overall; 3.4% highest-volume vs 5.8% lowest-volume centers; risk-adjusted mortality rises steeply below ~30–40 procedures/yr (Hughes 2013, PMID 22306215)
Acute type A dissection repair, US national (2003–2008) 21.6% overall; 27.5% (surgeons <1 case/yr) vs 17.0% (≥5/yr); institutions ≤3/yr 27.4% vs >13/yr 16.4% (Chikwe 2013, PMID 23562465)
Acute type A dissection, IRAD 1995–2013 In-hospital mortality fell 31%→22%; surgical mortality 25%→18%; surgical management rose 79%→90% (Pape 2015, PMID 26205591)
Elective valve-preserving root surgery (single expert center) ~1% (Yacoub elective 0.97%; David operative 1.1%) (Yacoub 1998, PMID 9605078; David 2021, PMID 33008570)

This order-of-magnitude elective-vs-emergency gap is the entire case for prophylactic surgery at size thresholds, and the volume gradient is the case for the 2022 guideline's Multidisciplinary Aortic Team construct — urgent repairs decided by a multidisciplinary team (1, C-EO), and referral of complex/asymptomatic cases to high-volume centers (≥30–40 aortic procedures/yr) with experienced surgeons (2a, C-LD) (Isselbacher 2022, PMID 36322642).

Aortic arch

  • Hemiarch: when aneurysm extends into the proximal arch during ascending repair, extending to a hemiarch is reasonable (2a); adding hemiarch has not been shown to increase operative risk when the proximal arch is diseased, but is not justified for a disease-free arch except in aortopathy expected to dilate (Isselbacher 2022, PMID 36322642).
  • Total arch ± elephant trunk: for arch aneurysm extending into the proximal descending aorta, a (conventional) elephant trunk may be considered (2b, C-LD) — a dangling graft extension that stages the later open or endovascular descending repair (Isselbacher 2022, PMID 36322642).
  • Frozen elephant trunk (FET): hybrid single-stage arch + stented descending repair. In acute DeBakey I dissection (72 patients, Cleveland Clinic), operative mortality 4.2%, stroke 4.2%, spinal cord injury 4.2%, 5-yr survival 80%, false-lumen thrombosis 92% (Roselli 2018, PMID 29217087). Pooled across 43 studies/5,068 patients (aneurysm and dissection): distal stent-graft-induced new entry 2%, endoleak 3%, secondary TEVAR 7%, false-lumen thrombosis at stent level 91% (Nakhaei 2022, PMID 36069163). FET trades single-stage completeness against spinal-cord risk and device-specific complications (dSINE).
  • High-surgical-risk arch aneurysm: hybrid/endovascular arch approaches may be reasonable (2b, C-EO); branched arch endografts remain investigational (Isselbacher 2022, PMID 36322642).

Descending and thoracoabdominal aorta

Choice of repair. In patients without Marfan, Loeys-Dietz, or vascular Ehlers-Danlos who meet criteria and have suitable anatomy, TEVAR is recommended over open surgery (1, B-NR); open repair is reasonable when anatomy is unsuitable (2a, B-NR); for rupture, TEVAR is preferred when anatomically feasible (1, B-NR) (Isselbacher 2022, PMID 36322642). Connective-tissue-disease patients get open repair because landing zones dilate and stent-graft radial force injures fragile aortas — see syndromic aortopathies.

Evidence base for TEVAR vs open (no RCT): meta-analysis of 42 nonrandomized studies, 5,888 patients — TEVAR reduced 30-day all-cause mortality (OR 0.44, 95% CI 0.33–0.59) and paraplegia (OR 0.42), plus transfusion, renal dysfunction, pneumonia, length of stay; no difference in mortality beyond 1 year — early advantage without proven late survival benefit (Cheng 2010, PMID 20137879). TEVAR outside trial-tested anatomic criteria is associated with late sac enlargement, hence the emphasis on patient selection and lifelong surveillance (Isselbacher 2022, PMID 36322642).

Open thoracoabdominal repair at an expert center (3,309 Crawford I–IV repairs, Baylor 1986–2014): operative death 7.5%, permanent paraplegia 2.9%, paraparesis 2.4%, permanent renal failure 5.7%, stroke 2.2%; composite adverse event highest for extent II (19.0%); survival 63.6% at 5 yr (Coselli 2016, PMID 26898979). These are benchmark — not average — numbers.

Spinal cord protection. The one RCT in this entire page: cerebrospinal fluid drainage during extent I/II TAAA repair cut paraplegia/paraparesis from 13.0% to 2.6% (p=0.03; 80% relative risk reduction) (Coselli 2002, PMID 11932655). The 2022 guideline makes CSF drainage Class 1 (LOE A) for open TAAA repair at high spinal-cord-injury risk, adds timely CSF drainage + perfusion-pressure rescue for delayed deficits (1, B-NR), and requires left subclavian revascularization before TEVAR with planned LSA coverage (1, B-NR) (Isselbacher 2022, PMID 36322642).

The ascending frontier: endovascular repair and PEARS

Ascending/arch TEVAR. No ascending-specific endograft is approved; ~10–20% of type A dissection patients are denied open surgery, motivating device development (Roselli 2023, PMID 35587698). ARISE (first-in-human GORE Ascending Stent Graft, 19 high-risk ascending-dissection patients): technically successful delivery in all; 30-day mortality 15.8%, disabling stroke 5.3% — promising for inoperable patients, far from elective-aneurysm territory (Roselli 2023, PMID 35587698). The 2022 guideline treats ascending endografting as investigational within trials (Isselbacher 2022, PMID 36322642).

Personalized External Aortic Root Support (PEARS/ExoVasc). A patient-specific polymer mesh sleeve, manufactured from a 3D-printed replica of the individual's root, implanted around the intact aorta to support and stabilize the wall — the native valve is left in place. MRI follow-up of the first 24 Marfan patients (root 45 ± 2.8 mm at implant): no root or ascending growth over 6.3 ± 2.6 years (root change −0.37 mm; ascending −0.10 mm), while the unsupported descending aorta grew +1.32 mm (p<0.001) — an internally controlled demonstration of mechanical efficacy (Izgi 2018, PMID 30165980). By 2022, ~700 implants across 30 centers in 12 countries; median Marfan root diameter at operation 47 mm; estimated perioperative mortality <0.3%; dimensional stability maintained where the operative protocol was followed (Treasure 2022, PMID 36094493). Caveats: observational, selected patients, no randomized comparison against VSRR, and no US-guideline endorsement (absent from the 2022 ACC/AHA recommendations; Isselbacher 2022, PMID 36322642).

Postoperative surveillance

After TEVAR: CT at 1 month and 12 months, then annually (1, B-NR); MRI as radiation-sparing alternative (2a, B-NR). After open repair without residual aortopathy: CT/MRI within 1 year then every 5 years (2a, B-NR); annual imaging with residual aortopathy or abnormal findings (2a, C-EO) (Isselbacher 2022, PMID 36322642). Rationale and technique: imaging and surveillance. The Toronto Marfan data justify lifelong whole-aorta vigilance — late deaths after successful root repair were driven by distal dissection, not by the repaired segment (David 2015, PMID 26403341).

Open questions

  • Valve-sparing vs Bentall has never been randomized; long-term AI slowly accrues after reimplantation (10.2% moderate-severe at 20 yr; David 2021, PMID 33008570) — for which patients does a durable bioprosthetic Bentall actually beat VSRR?
  • Does FET's single-stage benefit outweigh dSINE/reintervention (2%/7% pooled) versus staged conventional elephant trunk for chronic aneurysmal arch disease? No randomized data (Nakhaei 2022, PMID 36069163; Isselbacher 2022, PMID 36322642).
  • TEVAR's early mortality advantage disappears by 1 year (Cheng 2010, PMID 20137879) — is there any long-horizon population in whom open descending repair is superior, and can a trial still be done?
  • Can ascending endografting reach elective aneurysm care, or will it remain a bailout for inoperable dissection (30-day mortality 15.8% in ARISE; Roselli 2023, PMID 35587698)?
  • Does PEARS change hard outcomes versus watchful waiting to VSRR at 50 mm? All current evidence is observational and root-focused; the descending aorta keeps growing (Izgi 2018, PMID 30165980; Treasure 2022, PMID 36094493).
  • How should care be regionalized given the volume–outcome gradients (Hughes 2013, PMID 22306215; Chikwe 2013, PMID 23562465) — and what happens to access if 5.0 cm surgery is restricted to high-volume Multidisciplinary Aortic Teams (Isselbacher 2022, PMID 36322642)?

References

  1. Bentall H, De Bono A. A technique for complete replacement of the ascending aorta. Thorax. 1968;23:338-339. PMID 5664694. doi:10.1136/thx.23.4.338
  2. Yacoub MH, Gehle P, Chandrasekaran V, et al. Late results of a valve-preserving operation in patients with aneurysms of the ascending aorta and root. J Thorac Cardiovasc Surg. 1998;115:1080-1090. PMID 9605078. doi:10.1016/S0022-5223(98)70408-8
  3. David TE. Current readings: aortic valve-sparing operations. Semin Thorac Cardiovasc Surg. 2014;26:231-238. PMID 25527017. doi:10.1053/j.semtcvs.2014.10.002
  4. David TE, David CM, Ouzounian M, et al. A progress report on reimplantation of the aortic valve. J Thorac Cardiovasc Surg. 2021;161:890-899.e1. PMID 33008570. doi:10.1016/j.jtcvs.2020.07.121
  5. David TE, David CM, Manlhiot C, et al. Outcomes of aortic valve-sparing operations in Marfan syndrome. J Am Coll Cardiol. 2015;66:1445-1453. PMID 26403341. doi:10.1016/j.jacc.2015.07.041
  6. Isselbacher EM, Preventza O, Hamilton Black J, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022;146:e334-e482. PMID 36322642. doi:10.1161/CIR.0000000000001106
  7. Hughes GC, Zhao Y, Rankin JS, et al. Effects of institutional volumes on operative outcomes for aortic root replacement in North America. J Thorac Cardiovasc Surg. 2013;145:166-170. PMID 22306215. doi:10.1016/j.jtcvs.2011.10.094
  8. Chikwe J, Cavallaro P, Itagaki S, et al. National outcomes in acute aortic dissection: influence of surgeon and institutional volume on operative mortality. Ann Thorac Surg. 2013;95:1563-1569. PMID 23562465. doi:10.1016/j.athoracsur.2013.02.039
  9. Pape LA, Awais M, Woznicki EM, et al. Presentation, diagnosis, and outcomes of acute aortic dissection: 17-year trends from IRAD. J Am Coll Cardiol. 2015;66:350-358. PMID 26205591. doi:10.1016/j.jacc.2015.05.029
  10. Roselli EE, Idrees JJ, Bakaeen FG, et al. Evolution of simplified frozen elephant trunk repair for acute DeBakey type I dissection: midterm outcomes. Ann Thorac Surg. 2018;105:749-755. PMID 29217087. doi:10.1016/j.athoracsur.2017.08.037
  11. Nakhaei P, Bashir M, Jubouri M, et al. Aortic remodeling, distal stent-graft induced new entry and endoleak following frozen elephant trunk: a systematic review and meta-analysis. J Card Surg. 2022;37:3848-3862. PMID 36069163. doi:10.1111/jocs.16918
  12. Cheng D, Martin J, Shennib H, et al. Endovascular aortic repair versus open surgical repair for descending thoracic aortic disease: a systematic review and meta-analysis of comparative studies. J Am Coll Cardiol. 2010;55:986-1001. PMID 20137879. doi:10.1016/j.jacc.2009.11.047
  13. Coselli JS, LeMaire SA, Preventza O, et al. Outcomes of 3309 thoracoabdominal aortic aneurysm repairs. J Thorac Cardiovasc Surg. 2016;151:1323-1337. PMID 26898979. doi:10.1016/j.jtcvs.2015.12.050
  14. Coselli JS, LeMaire SA, Köksoy C, et al. Cerebrospinal fluid drainage reduces paraplegia after thoracoabdominal aortic aneurysm repair: results of a randomized clinical trial. J Vasc Surg. 2002;35:631-639. PMID 11932655. doi:10.1067/mva.2002.122024
  15. Roselli EE, Atkins MD, Brinkman W, et al. ARISE: first-in-human evaluation of a novel stent graft to treat ascending aortic dissection. J Endovasc Ther. 2023;30:550-560. PMID 35587698. doi:10.1177/15266028221095018
  16. Izgi C, Newsome S, Alpendurada F, et al. External aortic root support to prevent aortic dilatation in patients with Marfan syndrome. J Am Coll Cardiol. 2018;72:1095-1105. PMID 30165980. doi:10.1016/j.jacc.2018.06.053
  17. Treasure T, Austin C, Kenny LA, Pepper J. Personalized external aortic root support in aneurysm disease. Curr Opin Cardiol. 2022;37:454-458. PMID 36094493. doi:10.1097/HCO.0000000000000990